Core Capital Management & Research, inc.’s AstraZeneca AZN Stock Holding History

Core Capital Management & Research, inc.’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.7K	Buy	+100	New	+$18.8K	0.01%	146

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Core Capital Management & Research, inc.'s AZN Position: Q2 2026 in Review

Core Capital Management & Research, inc. opened a new position in AstraZeneca (AZN) in Q2 2026: 100 shares worth $16.7K. The stake represents 0.01% of the portfolio and ranks #146 among its holdings.

1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Core Capital Management & Research, inc. held 100 shares of AstraZeneca worth $16.7K as of Q2 2026.
AstraZeneca was a new Core Capital Management & Research, inc. position in Q2 2026.
AstraZeneca made up 0.01% of Core Capital Management & Research, inc.'s portfolio in Q2 2026, its #146 holding.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Core Capital Management & Research, inc.'s 13F filing for Q2 2026, filed 9 Sep 2026.